Skip to main content
Angiogenesis is an important process, which sustains ovarian cancer growth. Cediranib, a potent, oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3, and c-kit, has shown promise in other solid tumors, including non-small cell lung cancer.

Anti-angiogenesis Targeting Agents in Recurrent Ovarian Cancer: Now There Are Two?

January 1, 2010

Angiogenesis is an important process, which sustains ovarian cancer growth. Cediranib, a potent, oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3, and c-kit, has shown promise in other solid tumors, including non-small cell lung cancer.